Filing Details
- Accession Number:
- 0001181431-13-019376
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2013-03-28 17:44:18
- Reporting Period:
- 2013-03-26
- Filing Date:
- 2013-03-28
- Accepted Time:
- 2013-03-28 17:44:18
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1001233 | Sangamo Biosciences Inc | SGMO | Biological Products, (No Disgnostic Substances) (2836) | 680359556 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1202278 | G Dale Ando | C/O Sangamo Biosciences Inc. Point Richmond Tech Cntr, 501 Canal Blvd Richmond CA 94804 | Vp, Therapeutic Dev. & Cmo | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2013-03-26 | 5,800 | $3.61 | 94,598 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2013-03-26 | 9,200 | $3.61 | 103,798 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2013-03-26 | 15,000 | $9.18 | 88,798 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Employee Stock Option (Right to Buy) | Disposition | 2013-03-26 | 5,800 | $0.00 | 5,800 | $3.61 |
| Common Stock | Employee Stock Option (Right to Buy) | Disposition | 2013-03-26 | 9,200 | $0.00 | 9,200 | $3.61 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2014-08-01 | No | 4 | M | Direct | |
| 80,000 | 2014-08-01 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to the Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2012, as amended on September 12, 2012.
- Includes 50,000 shares and 35,000 shares subject to restricted stock units granted on December 8, 2011 and December 6, 2012, respectively, which will be issued as such units vest in accordance with their terms.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.08 to $9.30, inclusive. The Reporting Person undertakes to provide to Sangamo BioSciences, Inc., any security holder of Sangamo BioSciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
- All shares underlying this option are vested and immediately exercisable.
Billionaire Hedge Funds
